| 4 | AQR CAPITAL MANAGEMENT LLC | 6.6M | $214.1M | +43.3% | 6.661% | 0.07% |
| 5 | STATE STREET CORP | 6.2M | $205.6M | +22.7% | 6.253% | 0.00% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 4.3M | $143.5M | +2.5% | 4.362% | 0.00% |
| 7 | TWO SIGMA INVESTMENTS, LP | 3.6M | $120.9M | +64.2% | 3.677% | 0.09% |
| 8 | SANDS CAPITAL MANAGEMENT, LLC | 3.2M | $105.5M | -1.8% | 3.207% | 0.39% |
| 9 | JACOBS LEVY EQUITY MANAGEMENT, INC | 2.9M | $98.2M | +105.4% | 2.985% | 0.35% |
| 10 | FRONTIER CAPITAL MANAGEMENT CO LLC | 2.8M | $95.1M | +30.0% | 2.892% | 0.89% |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 2.6M | $86.1M | +39.4% | 2.618% | 0.00% |
| 12 | Sofinnova Investments, Inc. | 2.2M | $74.0M | -36.6% | 2.252% | 3.83% |
| 13 | Bellevue Group AG | 2.0M | $66.2M | -16.7% | 2.013% | 1.39% |
| 14 | D. E. Shaw & Co., Inc. | 1.7M | $57.8M | +37.2% | 1.757% | 0.03% |
| 15 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.6M | $52.8M | +229.2% | 1.604% | 0.07% |
| 16 | MPM BioImpact LLC | 1.4M | $47.4M | — | 1.440% | 2.89% |
| 17 | MORGAN STANLEY | 1.3M | $44.2M | -11.7% | 1.345% | 0.00% |
| 18 | Caption Management, LLC | 1.3M | $42.1M | +70.4% | 1.280% | 0.20% |
| 19 | WELLINGTON MANAGEMENT GROUP LLP | 1.3M | $41.8M | -52.6% | 1.270% | 0.01% |
| 20 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 1.2M | $41.5M | -13.0% | 1.261% | 0.18% |
| 21 | BANK OF AMERICA CORP /DE/ | 1.1M | $38.3M | +9.7% | 1.166% | 0.00% |
| 22 | Candriam S.C.A. | 1.0M | $33.4M | -8.6% | 1.017% | 0.15% |
| 23 | Rock Springs Capital Management LP | 968K | $32.3M | -20.6% | 0.983% | 1.58% |
| 24 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 966K | $32.3M | -15.0% | 0.981% | 0.00% |
| 25 | Jefferies Financial Group Inc. | 930K | $31.0M | +5902.2% | 0.944% | 0.20% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in RARE — a direct measure of their conviction.
| 95.00% |
| +0.13 pp |
| $2.99B |
| 14% |
| Q4 2024 | 305 | +4.5% | 94.87% | +1.20 pp | $3.48B | 23% |
| Q3 2024 | 292 | — | 93.67% | — | $4.52B | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
58 institutions opened new positions in RARE during Q2 2026, while 38 fully exited. 213 added to existing positions and 38 trimmed.
RARE institutional ownership rose by 10.06 percentage points quarter-over-quarter, with a net change of +24 holders.
The top 10 institutions account for 51.3% of all reported 13F value in RARE, and the top 25 account for 71.6%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Ultragenyx Pharmaceutical Inc. (RARE) Institutional Ownership